Pacira Pharmaceuticals, Inc. Release: Exparel Use In Femoral Nerve Block For Total Knee Arthroplasty Further Supported By Additional Data From Phase 3 Pivotal Study, SNDA Submission Planned For Second Quarter 2014

Published: Apr 07, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PARSIPPANY, N.J. & CHICAGO--(BUSINESS WIRE)--Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced additional Phase 3 data supporting the efficacy and safety of EXPAREL® (bupivacaine liposome injectable suspension) to achieve a femoral nerve block in patients undergoing total knee arthroplasty. The Company previously announced results of the primary efficacy endpoint, a statistically significant reduction in cumulative pain scores over 72 hours compared to placebo (P<0.0001). Secondary endpoints presented at the 39th Annual Meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA) found that a higher percentage of patients who received EXPAREL were pain-free, consumed fewer opioids and reported higher satisfaction with their pain control.

Help employers find you! Check out all the jobs and post your resume.

Back to news